Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Hormone or other secreted growth regulatory factor,...
Reexamination Certificate
2003-06-06
2010-10-19
Spector, Lorraine (Department: 1647)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Hormone or other secreted growth regulatory factor,...
C530S398000, C514S008100
Reexamination Certificate
active
07815912
ABSTRACT:
One aspect of the present invention is concerned with a method of controlled ovarian hyperstimulation in a mammalian female, said method comprising the co-administration to said female of —a substance having follicle stimulating hormone activity (FSH substance) in an amount effective to stimulate multiple follicular development; —gonadotropin releasing hormone (GnRH) antagonist in an amount equivalent to a daily subcutaneous dose of at least 0.5 mg ganirelix to prevent a premature LH-surge; and —a LH substance in an amount effective to prevent or suppress symptoms of luteinising hormone (LH) deficiency resulting from the administration of the GnRH antagonist; followed by administering a meiosis and luteinisation inducing substance (ML substance) in an amount effective to stimulate resumption of meiosis and luteinisation, and wherein the LH substance is not obtained from the urine of human females. Another aspect of the to invention relates to a pharmaceutical kit for use in a method of controlled hyperstimulation, which kit comprises: —at least one parenteral or oral dosage unit containing one or more FSH substances in an amount equivalent to a subcutaneous dose of 50-1500 I.U. FSH; —at least one parenteral dosage unit containing one or more GnRH antagonists in an amount equivalent to a subcutaneous dose of 0.5-25 mg ganirelix; —at least one parenteral dosage unit containing one or more LH substances in an amount equivalent to a subcutaneous dose of 50-3000 I.U. recombinant LH; wherein the LH substance is not obtained from the urine of human females.
REFERENCES:
patent: 6585982 (2003-07-01), Grøndahl et al.
patent: 7341989 (2008-03-01), Hillier et al.
patent: 2003/0092628 (2003-05-01), de Greef et al.
patent: 2006/0217315 (2006-09-01), Coelingh Bennink et al.
patent: 0 788 799 (1997-08-01), None
patent: WO 98/58657 (1998-12-01), None
patent: WO 99/55357 (1999-11-01), None
patent: WO 01/00227 (2001-01-01), None
Hideyuki Ikenaga, The Clinical Significance of the Ratio in FSH/LH of Human Menopausal Gonadotropins in a Programmed Stimulation Regimen for IVF-ET, Acta Obst. Gynaec, JPH, 1995, vol. 47, No. 11, pp. 1223-1229 (with translation).
Christina Bergh, Recombinant Follicle Stimulating Hromone, Hum. Reprod., 1999, vol. 14, No. 6, pp. 1418-1419.
Scott, et al., Correlation of Follicular Diameter with Oocyte Recovery and Maturity at the Time of Transvaginal Follicular Aspiration, Journal of in Vitro Fertilization and Embryo Transfer, 1989, vol. 6, No. 2, pp. 73-75.
International Search Report of Int. Appln. No. PCT/NL2003/000370.
Al-Inany, H., et al., “GnRH Antagonist in Assisted Reproduction: a Cochrane Review,” Human Reproduction, vol. 17, No. 4, pp. 874-885 (2002).
Burgues, S., et al., “The Effectiveness and Safety of Recombinant Human LH to Support Follicular Development Induced by Recombinant Human FSH in WHO Group I Anovulation: Evidence from a Multicentre Study in Spain,” Human Reproduction, vol. 16, No. 12, pp. 2525-2532 (2001).
Fauser, B., et al., “Endocrine Profiles after Triggering of Final Oocyte Maturation with GnRH Agonist after Cotreatment with the GnRH Antagonist Ganirelix during Ovarian Hyperstimulation for in vitro Fertilization,” The Journal of Clinical Endocrinology and Metabolism, vol. 87; No. 2, pp. 709-715 (2002).
Krusche, C., et al., “The Progesterone Antagonist Onapristone Retards the Advanced Endometrial Transformation after Gonadotropin Stimulation in Rabbits,” Steroids, vol. 65, pp. 773-782 (2000).
Lisi, F., et al., “Use of Recombinant Follicle-Stimulating Hormone (Gonal F) and Recombinant Luteinizing Hormone (Luveris) for Multiple Follicular Stimulation in Patients with a Suboptimal Response to in vitro Fertilization,” Fertility and Sterility, vol. 79, No. 4, pp. 1037-1038 (Apr. 2003).
Ludwig, M., et al., “Developments in Drugs for Ovarian Stimulation,” Best Practice & Research Clinical Obstetrics & Gynaecology, vol. 17, No. 2, pp. 231-247 (2003).
Ron-El, R., et al., “Induction of Ovulation after GnRH Antagonists,” Human Reproduction Update 2000,European Society of Human Reproduction and Embrology ,vol. 6, No. 4, pp. 318-321 (2000).
Wikland, M., et al., “A Prospective, Randomized Comparison of Two Starting Doses of Recombinant FSH in Combination with Cetrorelix in Women Undergoing Ovarian Stimulation for IVF/ICSI,” Human Reproduction,European Society of Human Reproduction and Embrology,vol. 16, No. 8, pp. 1676-1681 (2001).
Bennink Herman Jan Tijmen Coelingh
Bunschoten Evert Johannes
Ares Trading S.A.
Howrey LLP
Spector Lorraine
LandOfFree
Method of controlled ovarian hyperstimulation and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of controlled ovarian hyperstimulation and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of controlled ovarian hyperstimulation and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4210500